Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Arvinas (NASDAQ:ARVN) management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differentiated therapies, while seeking partners for assets that m
Pfizer will gain early access to Chai-3, a previously undisclosed model that doubles the antibody design success rate of its predecessor
According to the agreement, Pfizer will become one of the first pharmaceutical companies to access Chai’s newly revealed Chai-3 model.
Even without its metabolic business, management argues Eli Lilly (LLY) would be one of the fastest-growing pharmaceutical companies in the industry. This is not a single-product story. The company's immunology, oncology, and neuroscience medicines collectively grew by 160%, showing the depth of its R&D engine.
Pfizer (NYSE:PFE) has entered a new licensing agreement with Chai Discovery to use artificial intelligence models for biologics drug discovery. The partnership focuses on applying advanced AI to identify and design potential therapeutic candidates across Pfizer's research programs. This development comes as large drug makers explore ways to use AI to streamline R&D and widen their pipelines. Pfizer shares most recently closed at $25.34, with the stock up 15.9% over the past year and down...
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AbbVie's FDA approval of Decnupaz for BPDCN marks its first blood cancer ADC and expands a strategy built on deals and internal development.
Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends and Axsome warded off generic competitors.
Durability, not yield, is the deciding factor.
Adaptive Biotechnologies (NASDAQ:ADPT) Chief Executive Officer and Co-Founder Chad Robins said the company is focused on expanding its minimal residual disease testing business while pursuing targeted partnerships for its Immune Medicine platform, during a presentation at William Blair’s Growth Stoc
These stocks pay between 4.2% and 6.7% in dividends.
If enacted, lawmakers will hold the right to monitor and restrict American companies from signing certain deals with Chinese entities.
AstraZeneca's oncology sales hit $6.8B in first-quarter 2026, fueled by key cancer drugs. New launches and late-stage pipeline assets support growth.
Pfizer (NYSE:PFE) and Merck (NYSE:MRK) both just closed earnings chapters that frame the 2026 dividend debate clearly. Pfizer wrapped fiscal 2025 with a $0.66 adjusted EPS Q4 beat. Merck followed with a Q1 2026 report dominated by a $9 billion Cidara acquisition charge. Two very different income stories for yield hunters. One Pays You to ... Pfizer vs Merck: Chasing High Yield vs Higher Returns
ABBV wins EU approval for Aquipta for acute migraine treatment in adults, adding a second approved indication in migraine.
Whichever one you choose, you'll need patience before you can see solid returns.
Pfizer (NYSE:PFE) reported breakthrough Phase 3 results for its BRAFTOVI combination in first-line metastatic colorectal cancer and TALZENNA combination in metastatic hormone-sensitive prostate cancer, presented at ASCO 2026. The BREAKWATER trial of BRAFTOVI with cetuximab and FOLFIRI in BRAF V600E mutated metastatic colorectal cancer showed strong efficacy signals in progression-free and overall survival. The TALAPRO-3 study of TALZENNA with XTANDI in hormone-sensitive prostate cancer...
We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Pfizer Inc. (NYSE:PFE) is one of the most undervalued stocks on this list. TheFly reported on May 27 that PFE and Innovent Biologics announced a global strategic licensing and collaboration agreement covering the research and development of 12 early-stage oncology programs, including […]
Pfizer (NYSE:PFE) is one of those names where the headline narrative (COVID hangover, patent cliff) keeps overshadowing what is actually a defensive cash machine trading at a single-digit forward multiple. After running the numbers, my view leans constructive, and the 24/7 Wall St. price target reflects that. PFE stock trades at $26.18, and our 24/7 ... Why Pfizer’s Current Price May Be Too Cheap to Ignore
PFE targets a catalyst-rich 2026 with pivotal obesity and oncology studies, key data readouts, and regulatory decisions across its pipeline.
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year.
Pfizer (NYSE:PFE) has entered a global oncology partnership with Innovent Biologics worth up to $10.5b, focused on up to 12 early stage cancer programs, including antibody drug conjugates and multi specific antibodies. The company also reported seven year follow up results from the Phase 3 CROWN trial, indicating sustained protection from LORBRENA against disease progression and brain metastases in ALK positive advanced lung cancer. Pfizer is currently trading at $26.18, with the stock up...
Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen their market positions.
Pfizer could attract investors if Warsh's "regime change" at the Fed leads to market turbulence.
Summit said Harmoni-6 is the first Phase 3 study to show a "statistically significant" survival advantage over a PD-1 inhibitor plus chemotherapy.
Investing.com -- GLP-1 weight-loss and diabetes drugs may have a future role in cancer prevention and treatment, according to new research highlighted by Citi ahead of the 2026 American Society of Clinical Oncology (ASCO) meeting, adding another potential growth avenue to an already booming drug class.
Pfizer is an over-100-year-old drug company going through a rough patch, which has happened before.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
